# CheckMate 067

Source: https://onco.cc/trials/checkmate-067/  
OnCo record `checkmate-067` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial with the longest immunotherapy follow-up: about half of patients on the combination are alive at 10 years.

## Summary

CheckMate 067, trial NCT01844505 sponsored by Bristol Myers Squibb and reported in 2015 with ten-year results in the New England Journal of Medicine, is the trial with the longest immunotherapy follow-up: about half of patients on nivolumab plus ipilimumab for untreated advanced melanoma are alive at ten years when melanoma-specific survival is counted. It randomised 945 patients to the combination, nivolumab alone or ipilimumab alone, met its co-primary progression-free survival endpoint, and established that immunotherapy can produce durable cures. Who needs the ipilimumab component and its toxicity remains the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-04
- Registry id: NCT01844505
- Phase: 3
- Setting: Untreated advanced melanoma: nivolumab + ipilimumab vs nivolumab vs ipilimumab
- Sponsor: BMS
- Enrolled: 945
- Result: 10-year OS 43% vs 37% vs 19%.
- Outcomes: Overall survival at 10 years: Nivolumab + ipilimumab 43% vs Nivolumab 37% vs Ipilimumab 19%; Median overall survival: Nivolumab + ipilimumab 71.9 months vs Nivolumab 36.9 months vs Ipilimumab 19.9 months; Melanoma-specific survival at 10 years: Nivolumab + ipilimumab 52% vs Nivolumab 44% vs Ipilimumab 23%; Progression-free survival (co-primary): Nivolumab + ipilimumab 11.5 months vs Nivolumab 6.9 months vs Ipilimumab 2.9 months, HR 0.42
- Replication: Replicated by CheckMate 069 (phase 2) and consistent with KEYNOTE-006 for single-agent PD-1; the longest immunotherapy follow-up in any solid tumour.

## Sources

- ClinicalTrials.gov NCT01844505: https://clinicaltrials.gov/study/NCT01844505

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- people: [Dirk Schadendorf](https://onco.cc/people/dirk-schadendorf/), [F. Stephen Hodi](https://onco.cc/people/f-stephen-hodi/), [James Larkin](https://onco.cc/people/james-larkin/), [Jedd D. Wolchok](https://onco.cc/people/jedd-wolchok/), [Michael A. Postow](https://onco.cc/people/michael-postow/), [Paolo A. Ascierto](https://onco.cc/people/paolo-ascierto/)
- key papers: [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/), [Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma](https://onco.cc/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/), [Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours](https://onco.cc/key-papers/paper-leach-allison-ctla4-blockade-science-1996/), [RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma](https://onco.cc/key-papers/paper-relativity-047-nejm-2022/)
- trials: [RELATIVITY-047](https://onco.cc/trials/relativity-047/)
- terms: [Hazard ratio (HR)](https://onco.cc/terms/hazard-ratio/), [Kaplan-Meier curve, censoring and proportional hazards](https://onco.cc/terms/kaplan-meier-curve/), [Landmark and milestone survival (5-year survival, median follow-up)](https://onco.cc/terms/landmark-survival/), [Overall survival (OS)](https://onco.cc/terms/os/), [Randomised trial](https://onco.cc/terms/randomised-trial/), [Stratified randomisation, allocation concealment and minimisation](https://onco.cc/terms/stratified-randomisation/)
- roadmaps: [Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity](https://onco.cc/roadmaps/immunotherapy-roadmap/)
- bottlenecks: [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/)
- ideas: [Treat the draining lymph node before removing it](https://onco.cc/ideas/idea-bio2-lymph-node-immune-priming/)
- institutions: [Istituto Nazionale Tumori IRCCS Fondazione G. Pascale](https://onco.cc/institutions/pascale-naples/), [West German Cancer Center (WTZ), University Hospital Essen](https://onco.cc/institutions/essen-wtz/)

---
JSON: https://onco.cc/api/v1/entities/checkmate-067.json